Patients with high-risk HER2+ eBC (defined in this study using pathologic staging as follows: patients with nodal involvement [T0–4, N1–3, M0]; or tumor size > 5 cm [T3–4, N0, M0]; or nodal involvement; or by clinical stage IIb, IIc, IIIa, IIIb, or IIIc in patients who received neoadjuvant therapy) were of particular interest in this study owing to evidence that, even when treated with HER2-directed therapies, up to 20% of patients with HER2+ eBC will experience disease recurrence within 8 years [17]. This evidence concerns the gene ERBB2 and neoplasm.